Our pipeline includes SYK, FLT3, EGFR mutants (single, double and triple), and FGFR4
signal network related disease pathways. Genosco’s core competence comes from its
know-how in generating selective kinase inhibitor of interest.
Our most advanced pipeline is SKI-O-703, a selective SYK inhibitor for rheumatoid arthritis (RA),
systemic lupus erythematosus (SLE) and idiopathic thrombocytopenic purpura (ITP)
in its clinical phase 1. Our second generation SYK inhibitor to treat peripheral T-cell lymphoma
caused by ITK-SYK, BTK inhibitor-insensitive diffuse large B-cell lymphoma (DLBCL)
will be a desirable asset for immuno-oncology and is in late lead optimization stage. G-801,
an FLT3 inhibitor for acute myeloid leukemia is in clinical phase 1 study. GNS-1480,
an EGFR mutant-selective inhibitor for non-small cell lung cancer
and its metastatic brain cancer is in the late preclinical study.
A selective FGFR4 inhibitor program for hepatocellular carcinoma is in lead optimization stage.